医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mead Johnson Launches Enfinitas® in China

2016年03月28日 PM07:06
このエントリーをはてなブックマークに追加


 

GLENVIEW, Ill.

Mead Johnson Nutrition Company (NYSE:MJN) today announced the launch of its new Enfinitas premium-priced product line in China, which will be rolling out in that market over the coming weeks.

“As noted previously, Mead Johnson continually strives to further broaden our science-based product portfolio,” commented Kasper Jakobsen, President and CEO. “We are pleased to be introducing Enfinitas and its meaningful benefits to consumers in China in support of our mission to help nourish the world’s children for the best start in life. Over time, we expect this product to strengthen our competitiveness in the fastest-growing segment of our category in China.”

Enfinitas adopts the very latest science and advanced technology in infant nutrition and is inspired by Mead Johnson’s comprehensive global research and findings in human milk. That research, which has accelerated over the past five years, has been carried out in cooperation with multiple authoritative scientific research institutions in studies covering populations in Asia, Europe, North America and South America.

Specifically customized for the China market and produced in the Netherlands, this new formulation has undergone extensive research. Enfinitas contains Lactoferrin and Milk Fat Globule Membrane (MFGM) – both of which are naturally present in breast milk and known to provide structural and functional benefits to infants. Together with the company’s gold standard level of DHA, these critical components help support brain development, immune system function and digestive health.

Additional information will be provided on the Mead Johnson Nutrition 2016 first quarter earnings conference call.

About Mead Johnson Nutrition

Mead Johnson, a global leader in pediatric nutrition, develops, manufactures, markets and distributes more than 70 products in over 50 markets worldwide. The company’s mission is to nourish the world’s children for the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 110 years. The company’s “Enfa” family of brands, including Enfamil® infant formula, is the world’s leading brand franchise in pediatric nutrition. For more information, go to www.meadjohnson.com.

Forward-Looking Statements

Certain statements in this news release are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by the fact they use words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression. Such statements are likely to relate to, among other things, a discussion of goals, plans and projections regarding financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, capital expenditures, performance or results of current and anticipated products and the outcome of contingencies such as legal proceedings and financial results. Forward-looking statements can also be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations that involve inherent risks, uncertainties and assumptions that may cause actual results to differ materially from expectations as of the date of this news release. These risks include, but are not limited to: (1) the ability to sustain brand strength, particularly the Enfa family of brands; (2) the effect on the company’s reputation of real or perceived quality issues; (3) the effect of regulatory restrictions related to the company’s products; (4) the adverse effect of commodity costs; (5) increased competition from branded, private label, store and economy-branded products; (6) the effect of an economic downturn on consumers’ purchasing behavior and customers’ ability to pay for product; (7) inventory reductions by customers; (8) the adverse effect of changes in foreign currency exchange rates; (9) the effect of changes in economic, political and social conditions in the markets where we operate; (10) changing consumer preferences; (11) the possibility of changes in the WIC* program, or participation in WIC; (12) legislative, regulatory or judicial action that may adversely affect the company’s ability to advertise its products, maintain product margins, or negatively impact the company’s reputation or result in fines or penalties that decrease earnings; and (13) the ability to develop and market new, innovative products. For additional information regarding these and other factors, see the company’s filings with the United States Securities and Exchange Commission (the SEC), including its most recent Annual Report on Form 10-K, which filings are available upon request from the SEC or at www.meadjohnson.com. The company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

* The Special Supplemental Nutrition Program for Women, Infants and Children (WIC) is a federal assistance program of the Food and Nutrition Services (FNS) of the United States Department of Agriculture (USDA).

View source version on businesswire.com: http://www.businesswire.com/news/home/20160328005320/en/

CONTACT

Mead Johnson Nutrition Company
Investors:
Kathy MacDonald,
(847) 832-2182
kathy.macdonald@mjn.com
or
Media:
Christopher
Perille, (847) 832-2178
chris.perille@mjn.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ノボキュア社が日本で第2世代オプチューンの薬事承認を厚生労働省から取得
  • Heliae Announces First Use of Branded TruAzta Natural Astaxanthin
  • Visioneering Technologies, Inc. Successfully Lists on ASX
  • 中国のヘルスケア市場は今後15年間で投資と機会が急拡大の見込み
  • Dr. Reddy’s and Integra LifeSciences Enter into an Agreement to Market and Distribute DuraGen Plus® and Suturable DuraGen® Dural Regeneration in India